Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Imprinting in Metabolic Diseases - Identifying Epigenetic Mechanisms in Human Gestational Diabetes Through Cell-free DNA - Part B (Epi_GDM_B)

12 novembre 2026 aggiornato da: Martin Heni, University of Ulm

This clinical trial aims to investigate the development of and changes in fetal epigenetic signatures and how maternal metabolism influences these.

The metabolic profiles of the mother will be evaluated at three timepoints during pregnancy from a fasting blood sample and at another timepoints from an oral glucose tolerance test. Fetal epigenetic signatures can be identified by analyzing fetal cell-free DNA that circulates in the mother's bloodstream.

Panoramica dello studio

Descrizione dettagliata

Maternal metabolism during pregnancy plays an important role in fetal development and may influence the establishment and development of epigenetic signatures in the fetus. Epigenetic modifications, such as DNA methylation, regulate gene expression and are involved in numerous developmental processes. Alterations in these epigenetic patterns during pregnancy may have long-term consequences for offspring health and susceptibility to metabolic diseases. In particular, maternal metabolic conditions, including gestational diabetes mellitus (GDM), may influence fetal epigenetic programming. However, the dynamic development of fetal epigenetic signatures throughout pregnancy and their relationship with maternal metabolic changes remain insufficiently understood.

Investigating the fetal epigenome during pregnancy has long been challenging due to the limited availability of fetal tissue and the risks associated with invasive sampling procedures. The discovery of fetal cell-free DNA (cfDNA) circulating in maternal blood provides a non-invasive opportunity to investigate fetal characteristics during pregnancy. Recent advances in cell-free DNA analysis have made it possible not only to detect fetal genetic information but also to characterize fetal epigenetic signatures.

The primary objective of this study is to investigate the development and changes in fetal epigenetic signatures throughout pregnancy and to assess how maternal metabolic profiles influence these signatures. In particular, the study aims to identify associations between maternal metabolic parameters and fetal epigenetic modifications and to explore potential changes in these associations over the course of pregnancy. Furthermore, the study seeks to identify fetal epigenetic signatures associated with [specific maternal metabolic conditions, e.g. gestational diabetes mellitus] and to explore their potential as biomarkers of maternal metabolic status and fetal development.

To address these objectives, maternal metabolic profiles will be assessed at three time points during pregnancy using fasting blood samples collected at 11+0-13+6, 19+0-24+0, and 28+0-34+0. Fetal health will be assessed via ultrasound measures at these timepoints. Maternal glucose metabolism will be characterized using an oral glucose tolerance test (OGTT) at 24+0-27+6. Fetal epigenetic signatures will be investigated by analyzing fetal cell-free DNA circulating in maternal blood samples collected at all four timepoints.

By combining longitudinal maternal metabolic assessments with the analysis of fetal epigenetic signatures, this study aims to provide new insights into the relationship between maternal metabolism and fetal epigenetic development during pregnancy. The findings may contribute to a better understanding of the mechanisms underlying fetal metabolic programming and the potential long-term consequences of altered maternal metabolism for offspring health.

Tipo di studio

Osservativo

Iscrizione (Stimato)

15

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Femmina

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Participants will be recruited from public advertisements posted at Ulm University as well as through cooperations with local gynecologists.

Descrizione

Inclusion Criteria:

  • Pregnant women from gestational week 13+0
  • No known underlying medical conditions i
  • No known underlying diseases
  • Understanding and voluntary signing of a consent form before study- related examinations

Exclusion Criteria:

  • Age < 18 years
  • Type 1 or type 2 diabetes mellitus
  • Pharmacological treatment affecting blood glucose levels (e.g., steroids, insulin)
  • Endocrine disorders (e.g., hyperthyroidism, polycystic ovary syndrome [PCOS])
  • Current depression or other psychiatric disorders
  • Eating disorders
  • Regular use of medication during pregnancy
  • Pre-existing cardiovascular disease
  • Drug and/or alcohol abuse
  • Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m²
  • C-reactive protein > 10 mg/l
  • Transaminase elevation of 2 times the upper norm
  • No consent to be informed about incidentally discovered pathological findings
  • Any other (clinical) condition that would endanger participants safety or question scientific success according to the physicians opinion.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: FAMILY_BASED
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Pregnant women

Metabolic and epigenetic characterization

Maternal metabolic profiles will be assessed at three time points during pregnancy using fasting blood samples and at an additional time point using an oral glucose tolerance test (OGTT). Fetal epigenetic signatures will be investigated through the analysis of fetal cell-free DNA circulating in maternal blood. Fetal health will be assessed by ultrasound at the timepoints of the fasting blood samples No therapeutic intervention will be performed.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Epigenetic profiles of mothers and fetuses
Lasso di tempo: Gestational weeks 13+0 - 34+0

Methylation pattern of CpG sites in fathers, mothers and fetuses assessed from blood samples from the father and the mother.

Genome-wide DNA methylation will be quantified as 5-methylcytosine (5mC) levels at CpG sites in maternal and paternal nuclear DNA from peripheral blood. Long-read sequencing will be used to detect genomic sequences and base modifications. Fetal DNA methylation will be assessed from fetal cell-free DNA isolated from maternal plasma using long-read sequencing. Allelic phasing will be applied to assign epigenetic modifications to parental origin. Deconvolution analysis will be used to subtract blood cell-derived epigenetic patterns and infer tissue-of-origin signals.

Gestational weeks 13+0 - 34+0
Changes in epigenetic profiles of mothers and fetuses during pregnancy
Lasso di tempo: Gestational weeks 13+0 - 34+0

Changes in epigenetic profiles as determined in Primary Outcome 1 during pregnancy.

Gestational weeks 13+0 - 34+0

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Epigenetic signatures of gestational diabetes
Lasso di tempo: Gestational weeks 13+0 - 34+0

Differentially methylated regions will be computed across parental genomic DNA and fetal cell-free DNA between women with and without gestational diabetes. Differentially methylated regions will be bioinformatically annotated to candidate genes and pathogenic pathways.

Gestational weeks 13+0 - 34+0
Correlation of epigenetic signatures and glycemia
Lasso di tempo: Gestational weeks 13+0 - 34+0

Glucose level assessed from glucose measurements from fasting blood sample or oral glucose tolerance test.

Gestational weeks 13+0 - 34+0
Correlation of epigenetic signatures with weight gain
Lasso di tempo: Gestational weeks 13+0 - 34+0

Correlation of changes in epigenetic signatures as assessed in primary outcome 2 with maternal weight gain.

Gestational weeks 13+0 - 34+0
Correlation of epigenetic signatures and insulin sensitivity
Lasso di tempo: Gestational weeks 13+0 - 34+0

Insulin sensitivity assessed by Homeostasis Model Assessment of insulin resistance based on glucose and insulin measurements from fasting blood sample or oral glucose tolerance test.

Gestational weeks 13+0 - 34+0
Correlation of epigenetic signatures and insulin secretion
Lasso di tempo: Gestational weeks 13+0 - 34+0

Insulin secretion assessed by Homeostasis Model Assessment of beta-cell function based on glucose and insulin measurements from fasting blood sample and oral glucose tolerance test.

Gestational weeks 13+0 - 34+0
Correlation of epigenetic signatures and lipids
Lasso di tempo: Gestational weeks 13+0 - 34+0

Lipid profiles assessed from lipid measurements from fasting blood sample.

Gestational weeks 13+0 - 34+0
Correlation of of epigenetic signatures with anthropometric features of the fetus
Lasso di tempo: Gestational weeks 13+0 - 34+0

Correlation of epigenetic signatures as assessed by primary outcome 1 with anthropometric features of the features assessed by ultrasound.

Gestational weeks 13+0 - 34+0

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 gennaio 2027

Completamento primario (Stimato)

31 dicembre 2028

Completamento dello studio (Stimato)

30 giugno 2029

Date di iscrizione allo studio

Primo inviato

12 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

12 novembre 2026

Primo Inserito (Effettivo)

18 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi